Its lead product, Baremsis (amisulpride injection), has been filed with the US Food and Drug Administration for the treatment and prophylaxis of post-operative nausea & vomiting following successful completion of Phase III pivotal trials.

The UK-based company is also developing APD403, which is in Phase II trials for chemotherapy-induced nausea & vomiting.